clinical trial · NCT06841679
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.·phase3·recruiting·n = 778
Gastric or Gastroesophageal Junction AdenocarcinomaUtidelone CapsuleUtidelone CapsuleUtidelone CapsuleFluoropyrimidine- and Platinum-containing TherapyOxaliplatinUtidelone CapsulePD-1 inhibitorCapecitabine
brief summary
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.
started
Aug 28, 2025
primary completion
Sep 1, 2030
completion
Sep 1, 2030
last updated
Nov 25, 2025
official title
A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol